zurück

Empagliflozin (new indication: chronic heart failure)

Subject:

  • Active Substance: Empagliflozin
  • Name: Jardiance®
  • Therapeutic area: Chronic heart failure
  • Pharmaceutical company: Boehringer Ingelheim Pharma GmbH & Co. KG

Time table:

  • Start: 15.07.2021
  • Final decision by G-BA: 06.01.2022

Final decision:

  • Hint for a minor additional benefit